Medannex: Funding, Investors & Team (Oct 2026)
Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases. Following a recent Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.
Medannex has raised $400k across 1 funding round on record, the most recent an undisclosed round of $400k announced in Jul 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Medannex Company Profile and Key Stats
Latest funding round on record: Jul 2024.
Medannex Funding Rounds
Medannex Founders and Leadership Team
No contact details are on record for this team yet.
Medannex Funding Compared to Other Biotechnology Startups
Medannex's latest round of $400k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Medannex in Biotechnology and Edinburgh
Companies Similar to Medannex
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Medannex Funding FAQs
What does Medannex do?
Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases. Following a recent Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.
How much funding has Medannex raised?
Medannex has raised $400k across 1 round on record. The most recent is an undisclosed round of $400k announced in Jul 2024.
When did Medannex last raise funding?
Medannex's most recent funding round on record is an undisclosed round of $400k, announced in Jul 2024.
Who founded Medannex?
FundedIQ lists Afri Wansyah (Founder) at Medannex.
Where is Medannex headquartered?
Medannex is based in Edinburgh, United Kingdom.
How many employees does Medannex have?
Medannex is in the 11-50 employee band.
How does Medannex's funding compare to other Biotechnology startups?
Medannex's latest round of $400k is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Medannex Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Medannex is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.